Paving the Way for Sustained Growth: Rapid Nutrition’s 2024 Achievements and 2025 Roadmap

03 Dec 2024 05:05 CET

Paving the Way for Sustained Growth: 

Rapid Nutrition’s 2024 Achievements and 2025 Roadmap

London, United Kingdom, December 3, 2024 – Rapid Nutrition PLC (Euronext: ALRPD), a global health and wellness company, today shared its year-end update, highlighting key achievements in 2024 and outlining its strategic priorities for 2025. Strengthened by strategic initiatives and market expansions, the company remains focused on sustainable growth and enhancing shareholder value. 

2024 Performance Highlights

In 2024, Rapid Nutrition made significant progress in its growth strategy, achieving key milestones:

• Market Expansion: Successfully completed its first manufacturing run in China, aligning with major sales events such as Singles’ Day and Black Friday. Additionally, the company has established a U.S. warehouse in Utah to support North American operations and is expanding into neighboring markets, including Korea and Japan, with its patented herbal antiviral Azurene and SystemLS products.

• Clinical Validation: Participated in a landmark U.S. clinical trial focused on osteoarthritis prevention, reinforcing SystemLS’s scientific credibility and premium positioning.

• Financial Strength: Early conversion of the final convertible note ahead of schedule strengthened the company’s financial foundation for reinvestment in growth markets.

• Operational Scalability: Optimized supply chain processes to support broader market penetration and efficiency in 2025 and beyond.

CEO Simon St Ledger remarked:
"2024 marked a transformative year for Rapid Nutrition. Our operational excellence, strategic market entries, and localized product development have positioned us to capitalize on opportunities in China, North America, and the broader APAC region. As we look to 2025, our focus remains on innovation and sustainable growth."

2025 Strategic Priorities

Building on its momentum, Rapid Nutrition has outlined a phased roadmap to achieve its growth targets:

• China Market Growth: Anticipates $1.5 million in revenue, supported by tailored products and streamlined production processes.

• Subscription Model Expansion: Scaling the proven SystemLS subscription model in Australia to North America, leveraging inventory in the U.S. warehouse to replicate success in a high-potential market.

• Clinical Validation: U.S. expansion bolstered by an ongoing university-led clinical trial, further enhancing the SystemLS brand’s scientific validation.

• APAC Opportunities: A recent distribution agreement in Korea and increasing demand in Southeast Asia contribute to Rapid Nutrition’s broader growth strategy, which we will see flow through to the company’s topline revenue in 2025.

Southeast Asia: A Catalyst for Growth

Southeast Asia, with its dynamic economies and ambitious growth trajectory, presents a significant opportunity for Rapid Nutrition. The company’s innovative products, strategic partnerships, and presence in key markets like China and Korea position it to benefit from the region’s economic vitality and foster long-term growth.

Outlook for 2025

Rapid Nutrition remains committed to disciplined execution and value creation, supported by an optimized supply chain, global market expansion, and continuous innovation.

"As we enter 2025, our roadmap—anchored in China’s rapid growth potential and complemented by expansion in the U.S. and APAC—positions Rapid Nutrition for impactful and sustainable progress," said Simon St Ledger.

For more information about Rapid Nutrition PLC and its product offerings, including market insights, please visit www.rnplc.com.

About Rapid Nutrition

Rapid Nutrition is a leading health and wellness company committed to providing innovative solutions for a healthier world. With a focus on research-backed formulas, we empower individuals to optimize their well-being and face life's challenges with confidence.

Investor Relations Contact:

ir@rnplc.com

Disclaimer

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).